1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,824 | 0,848 | 11:24 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CERENO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
| 06.08. | Cereno Scientific announces conversion of convertibles following request by Fenja Capital II A/S and Arena Investors, LP | 2 | Cision News | ||
| 17.07. | Cereno Scientific - Phase II calling for CS014 after Phase I success | 294 | Edison Investment Research | Cereno Scientific reported positive Phase I readouts for CS014, its novel HDAC inhibitor, paving the way for Phase II studies in idiopathic pulmonary fibrosis (IPF). The candidate demonstrated favourable... ► Artikel lesen | |
| 15.07. | Cereno Scientific AB: Cereno Scientific announces positive topline results from Phase I trial of CS014 - a novel HDAC inhibitor - supporting advancement into Phase II | 86 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced positive... ► Artikel lesen | |
| 30.06. | Cereno Scientific shares that the top-line results of the CS014 Phase I trial will be communicated in mid-July | 4 | Cision News | ||
| 23.06. | Cereno Scientific - Improved liquidity with latest debt financing | 292 | Edison Investment Research | Cereno Scientific has bolstered its liquidity position through a SEK25m loan facility secured from new Danish investors Venusat and SAJ Finans. Concurrently, the company executed an addendum to its... ► Artikel lesen | |
| 20.06. | Cereno Scientific secures 100 MSEK through additional loan financing and conversion to advance HDAC inhibitors CS1 and CS014 in Phase II | 1 | Cision News | ||
| 17.06. | Cereno Scientific - Four-month EAP data support CS1 plans | 299 | Edison Investment Research | Cereno Scientific has announced encouraging four-month follow-up data from its Expanded Access Program (EAP) for CS1, a first-in-class HDAC inhibitor being developed to treat pulmonary arterial hypertension... ► Artikel lesen | |
| 16.06. | Cereno Scientific AB: Cereno Scientific shares 4-month follow-up data from Expanded Access Program in line with Phase IIa trial results of CS1 in rare disease PAH | 184 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced 4-month... ► Artikel lesen | |
| 10.06. | Cereno Scientific AB: Cereno Scientific shares the report from Annual General Meeting 2025 | 172 | GlobeNewswire (Europe) | Today, June 10, 2025 Cereno Scientific AB (publ) held Annual General Meeting at the MAQS Advokatbyrå's premises at Masthamnsgatan 13 in Gothenburg, Sweden. Chairman of the Annual General Meeting (the... ► Artikel lesen | |
| 27.05. | Cereno Scientific - Firing on all cylinders | 417 | Edison Investment Research | In Q125, Cereno made tangible progress across both its clinical programmes. The period opened with new data for lead asset CS1 indicating disease-modifying signals, and was capped by FDA endorsement... ► Artikel lesen | |
| 27.05. | Cereno Scientific is nominated and shortlisted for 'Company of the Year' in the European Mediscience Awards 2025 | 1 | Cision News | ||
| 23.05. | Cereno Scientific AB: Cereno Scientific receives endorsement from FDA on plans for Phase IIb trial of CS1 in rare disease pulmonary arterial hypertension (PAH) | 160 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 22.05. | Cereno Scientific AB: Cereno Scientific publishes Interim Report for Q1 2025 (January 1 - March 31, 2025) | 270 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 15.05. | Cereno Scientific publishes Annual Report for 2024 | 1 | Cision News | ||
| 13.05. | Cereno Scientific presented CS1's Phase IIa trial results at the 5th Baltic Pulmonary Hypertension Conference 2025 | 2 | Cision News | ||
| 09.05. | Cereno Scientific give notice to attend the Annual General Meeting 2025 | 1 | Cision News | ||
| 07.05. | Correction: Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on June 10, 2025 | 1 | Cision News | ||
| 07.05. | Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on May 10, 2025 | 2 | Cision News | ||
| 07.05. | Cereno Scientific to present at ABGSC Investor Days on May 13-14, 2025, in Stockholm | 1 | Cision News | ||
| 23.04. | Cereno Scientific - CS1 takes another step towards Phase IIb | 338 | Edison Investment Research | Cereno Scientific has successfully completed its planned Type C meeting with the FDA for lead asset CS1. The minutes from the meeting will be available after 30 days, but Cereno has indicated that the... ► Artikel lesen |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 46,230 | 0,00 % | Aktien New York: Erholungspfad wieder aufgenommen - Apple ziehen stark an | NEW YORK (dpa-AFX) - Die US-Börsen haben am Mittwoch nach dem etwas schwächeren Vortag wieder den Weg nach oben eingeschlagen. Für Bewegung sorgten positiv aufgenommene Nachrichten zu Apple sowie Unternehmensberichte.... ► Artikel lesen | |
| 180 LIFE SCIENCES | 10,270 | 0,00 % | 180 Life Sciences setzt auf Ethereum - Milliardenwechsel in Geschäftsstrategie | Die 180 Life Sciences Corp. (Börsenkürzel: ATNF) hat bekanntgegeben, inzwischen 82.186 Ether-Token zu halten - ein Bestand, der zum 11. August 2025 rund 349 Millionen US-Dollar wert war. Der durchschnittliche... ► Artikel lesen | |
| BEAM THERAPEUTICS | 16,860 | 0,00 % | Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) | With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,410 | 0,00 % | RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down | ||
| HARMONY BIOSCIENCES | 35,470 | 0,00 % | Mizuho raises Harmony Biosciences stock price target to $50 on increased confidence | ||
| SUMMIT THERAPEUTICS | 25,680 | 0,00 % | Evercore ISI hebt Kursziel für Summit Therapeutics auf 34 US-Dollar an | ||
| JANUX THERAPEUTICS | 24,270 | 0,00 % | Janux Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| EVOTEC | 6,698 | +1,79 % | Evotec Aktie: Die Bullen in der Falle? | Die Evotec Aktie steht erneut im Zentrum charttechnischer Spannung. Nachdem der Kurs der Biotech-Aktie Ende Juli kurzzeitig über die 200-Tage-Linie ausgebrochen war, entpuppte sich dieser Anstieg schnell... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 18,740 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights | Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 9,300 | 0,00 % | SIGA Technologies - A solid quarter for topline growth | Q225 was a strong quarter for SIGA, supported by material topline traction, with deliveries of $79m of oral and IV TPOXX to the US strategic national stockpile (SNS), fully servicing the order book... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 10,380 | 0,00 % | Phathom projects $165M-$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growth | ||
| NURIX THERAPEUTICS | 10,020 | 0,00 % | Nurix Therapeutics: Günstiger BTK-Player | In der Welt der Biotechnologie zählt die gezielte Zerstörung krankheitsverursachender Proteine zu den innovativsten Ansätzen der modernen Arzneimittelforschung. Nurix Therapeutics, ein Unternehmen mit... ► Artikel lesen | |
| VALNEVA | 4,420 | +11,22 % | Valneva: FDA gibt Chikungunya-Impfstoff IXCHIQ wieder frei | Valneva hat bekanntgegeben, dass die US-Arzneimittelbehörde FDA die zuvor empfohlene Einschränkung für den Chikungunya-Impfstoff IXCHIQ bei Personen ab 60 Jahren aufgehoben hat. Zugleich wurde eine... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,760 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,100 | 0,00 % | iTeos Therapeutics, Inc. - 10-Q, Quarterly Report |
CERENO SCIENTIFIC AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,817 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERENO SCIENTIFIC AB finden Sie auf Wallstreet Online.